Marshall Wace
RPRX

Marshall Wace’s Repros Therapeutics Inc. RPRX Stock Holding History

Marshall Wace’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,047
Closed -$72K – 1252
2015
Q2 		$72K Buy
+10,047
New +$78.3K ﹤0.01% 869

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Marshall Wace's RPRX Position: Q3 2015 in Review

Marshall Wace sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 10,047 shares — an estimated $72K sold.

Marshall Wace first reported a position in RPRX in Q2 2015 and held it in 1 quarter. The position peaked at $72K in Q2 2015. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

  • Marshall Wace reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
  • Marshall Wace sold 10,047 Repros Therapeutics Inc. shares in Q3 2015, an estimated $72K.
  • Marshall Wace first reported a position in Repros Therapeutics Inc. in Q2 2015 and held it in 1 quarter.
  • Marshall Wace's Repros Therapeutics Inc. position peaked at $72K in Q2 2015.
  • 58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on Marshall Wace's 13F filing for Q3 2015, filed 12 Nov 2015.